GlassScriptPhysician profile
Chuanxiang Chi
NPI 1609985506
$2,424.96
in general payments reported to CMS, 2019-2025
20 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,256 · 2020: $56.52 · 2021: $311 · 2022: $390 · 2023: $125 · 2024: $173 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $265.00 | 2021-2022 | |
| Incyte Corporation | $250.00 | 2019 | |
| Exelixis INC. | $222.24 | 2019 | |
| Gilead Sciences, INC. | $194.00 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2019 | |
| Beigene USA, INC. | $125.00 | 2021 | |
| Amgen INC. | $125.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2022 | |
| Janssen Biotech, INC. | $125.00 | 2023 | Tecvayli, Carvykti, Darzalex |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Ibsa Pharma INC. | $125.00 | 2024 | Licart |
| Takeda Pharmaceuticals U.S.A., INC. | $116.36 | 2019 | |
| Abbvie INC. | $112.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.93 | 2019 | |
| Bioventus LLC | $99.69 | 2025 | Durolane, Xcell, Gelsyn-3 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $93.02 | 2020-2021 | |
| Depuy Synthes Sales INC. | $24.82 | 2024 | Monovisc, Orthovisc |
| Scilex Pharmaceuticals INC. | $24.46 | 2020 | |
| Ucb, INC. | $23.52 | 2024 | Cimzia |
| Fidia Pharma USA INC. | $13.71 | 2025 | Hymhyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chuanxiang Chi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.